Friday - May 9, 2025

LOGIN  |  REGISTER
Terns Pharmaceuticals

Haemonetics 2nd Quarter Fiscal Year 2024 Earnings Release Available on Investor Relations Website

November 02, 2023 | Last Trade: US$68.01 3.76 5.85

BOSTON, Nov. 2, 2023 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2024, which ended September 30, 2023, are available on its Investor Relations website.

The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on November 2, 2023. The conference call and webcast can be accessed with the following information:

  • Teleconference link
  • Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
  • A live webcast of the call can be accessed on Haemonetics' investor relations website or via the following link: https://edge.media-server.com/mmc/p/twgnwbaw

In addition, the Company has posted to its Investor Relations website the earnings release that will be referenced on its conference call and webcast, a link to which is available below.  

Direct link to 2Q FY24 Earnings Release

A replay of the conference call and webcast will be available for one year beginning on November 2, 2023, at 11:00 a.m. ET using the conference call webcast link provided in this press release.

ABOUT HAEMONETICS

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.

Investor Contacts:             

 

Olga Guyette, Sr. Director-Investor Relations & Treasury  

David Trenk, Manager-Investor Relations

(781) 356-9763                                                                       

(203) 733-4987

olga.guyette@haemonetics.com                                            

david.trenk@haemonetics.com                                                                                 

Media Contact:          

 

Josh Gitelson, Director-Global Communications

 

(781) 356-9776

 

josh.gitelson@haemonetics.com 

 

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page